View Alert


Originator: CMO Messaging

 
From: Professor Chris Whitty

Issue date: 23-Jan-2020 14:54:25

Action by recipients:
  • NHS Regional Offices
  • NHS Foundation Trusts (England) - Medical Director
  • NHS Foundation Trusts (England) - Chief Executive
  • NHS Trusts (England) - Medical Director
  • Regional Directors of Public Health
  • CMO Urgent Messages - Recipients on Public Health Link
  • NHS Trusts (England) - Chief Executive

Information to recipients:
  • MHRA (Medicines) Drug Alerts (Various Recipients)
  • Other contacts
  • Independent Healthcare Providers (registered with CAS)
  • Clinical Commissioning Groups
  • Social Care Providers (registered with CAS)
  • Special Health Authorities
  • CMO Urgent Messages - Non-NHS Recipients on Public Health Link
  • MHRA (Medicines) Drug Alerts - Non-NHS Recipients
  • Territorial CMOs in Northern Ireland, Scotland & Wales
  • Consultants in Communicable Diseases
  • Director of Public Health
  • GP - Locum
  • NHS 111 and Out of hours providers
  • GP Practices
  • Primary Care Networks

Action category: Important information for immediate action

Title: Wuhan Novel Coronavirus

Broadcast content: There have been reported cases in China of respiratory infections caused by a novel coronavirus.

This alert and pathway outline the initial assessment questions to identify a patient who may require isolation and testing. All primary and secondary healthcare providers should make arrangements for such patients to be identified immediately and isolated according to the PHE guidance. The current patient pathway is for assessment in airborne isolation in an acute trust, followed by testing and a period of isolation (at home or in hospital) whilst awaiting the results.  



Additional information: NHS England Regional Offices: please cascade this alert to Community Pharmacy and to any GP Practices in your areas that are not yet registered with CAS.

Alert reference: CEM/CMO/2020/001

Attachments:

Contact our helpdesk

Email: safetyalerts@mhra.gov.uk

Medicines and Healthcare products Regulatory Agency